Notably, a recently published case report described a patient with CLL treated with BGB-16673, who was found to have the A428D mutation at the time of disease progression, suggesting that BGB-16673 may interact with BTK at or around A428 and confer a potential mechanism of resistance [84]. Here, BTK is linked to B-cell chronic lymphocytic leukemia.